Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
(RTTNews) - Certara, Inc. (CERT),on Tuesday announced the release of Simcyp Simulator Version 24, enhancing physiologically-based pharmacokinetic or PBPK modeling to support drug development and ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced the ...
Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
Simulations Plus (SLP) announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration FDA to use physiologically based pharmacokinetic PBPK approaches in GastroPlus ...
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® ...
Physiologically based pharmacokinetics (PBPK), as the name implies, is a special branch of pharmacokinetics where physiology and anatomy of the animal or human body, as well as the biochemistry of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results